

FILE 'USPAT' ENTERED AT 08:07:28 ON 24 FEB 1999  
\*\*\*\*\*  
\* WELCOME TO THE \*  
\* U.S. PATENT TEXT FILE \*  
\*\*\*\*\*  
=> s aav or adeno associated or adenoassociated  
266 AAV  
984 ADENO  
835148 ASSOCIATED  
442 ADENO ASSOCIATED  
(ADENO(W)ASSOCIATED)  
15 ADENOASSOCIATED  
L1 553 AAV OR ADENO ASSOCIATED OR ADENOASSOCIATED  
=> s transduc? or vector?  
97056 TRANSDUC?  
75552 VECTOR?  
L2 163262 TRANSDUC? OR VECTOR?  
=> s l1(p)l2  
L3 405 L1(P)L2  
=> s promoter or expression control?  
<-----User Break----->  
u  
SEARCH ENDED BY USER  
=> s (promoter# or expression control?)(p)l3  
34332 PROMOTER#  
83232 EXPRESSION  
1351700 CONTROL?  
1865 EXPRESSION CONTROL?  
(EXPRESSION(W)CONTROL?)  
L4 115 (PROMOTER# OR EXPRESSION CONTROL?)(P)L3  
=> d l-115  
1. 5,874,304, Feb. 23, 1999, Humanized green fluorescent protein genes and methods; Sergei Zolotukhin, et al., 435/366, 320.1, 325, 354, 357, 358, 365, 367; 536/23.1, 23.5 [IMAGE AVAILABLE]  
2. 5,872,005, Feb. 16, 1999, Packaging cell lines for adeno-associated viral vectors; Qing Wang, et al., 435/320.1, 369 [IMAGE AVAILABLE]  
3. 5,871,982, Feb. 16, 1999, Hybrid adenovirus-AAV virus and methods of use thereof; James M. Wilson, et al., 435/235.1, 320.1, 325 [IMAGE AVAILABLE]  
4. 5,869,306, Feb. 9, 1999, Gene transfer preparation; Hidekazu Kuma, et al., 435/320.1 [IMAGE AVAILABLE]  
5. 5,869,305, Feb. 9, 1999, Recombinant viral vector system; Richard

Jude Samulski, et al., 435/320.1, 369; 536/24.1 [IMAGE AVAILABLE]  
6. 5,866,696, Feb. 2, 1999, Modified \*\*adeno\*\*\*-\*\*associated\*\* virus \*\*vector\*\* capable of expression from a novel \*\*promoter\*\*; Barrie J. Carter, et al., 536/23.5, 24.1 [IMAGE AVAILABLE]  
7. 5,866,552, Feb. 2, 1999, Method for expressing a gene in the absence of an immune response; James M. Wilson, et al., 514/44; 424/93.21; 435/69.1, 320.1, 325 [IMAGE AVAILABLE]  
8. 5,863,541, Jan. 26, 1999, AAV capsid vehicles for molecular transfer; Richard Jude Samulski, et al., 424/192.1, 204.1, 234.1; 435/235.1, 320.1 [IMAGE AVAILABLE]  
9. 5,863,531, Jan. 26, 1999, In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework; Gail K. Naughton, et al., 424/93.7, 423; 435/174, 180, 182, 395, 398 [IMAGE AVAILABLE]  
10. 5,861,314, Jan. 19, 1999, Adeno-associated viral (AAV) liposomes and methods related thereto; Ramila Philip, et al., 435/372.3 [IMAGE AVAILABLE]  
11. 5,861,171, Jan. 19, 1999, Adeno-associated viral (AAV) liposomes and methods related thereto; Ramila Philip, et al., 424/450, 93.2, 93.6 [IMAGE AVAILABLE]  
12. 5,859,197, Jan. 12, 1999, Neurogene; Lars E. Theill, et al., 530/350, 300, 827, 839, 855 [IMAGE AVAILABLE]  
13. 5,859,195, Jan. 12, 1999, Neurofibromatosis gene; Francis S. Collins, et al., 530/350; 435/69.1; 530/828; 536/23.5, 24.31 [IMAGE AVAILABLE]  
14. 5,858,990, Jan. 12, 1999, Fas ligand compositions for treatment of proliferative disorders; Kenneth Walsh, 514/44; 435/6, 69.1, 320.1, 375, 377 [IMAGE AVAILABLE]  
15. 5,858,777, Jan. 12, 1999, Methods and reagents for regulating telomere length and telomerase activity; Bryant Villeponteau, et al., 435/325, 69.1, 91.3, 194, 252.3, 254.11, 320.1; 530/350; 536/23.2, 24.31 [IMAGE AVAILABLE]  
16. 5,858,775, Jan. 12, 1999, Adeno-associated virus materials and methods; Philip R. Johnson, 435/320.1; 536/23.1, 23.72 [IMAGE AVAILABLE]  
17. 5,858,351, Jan. 12, 1999, Methods for delivering DNA to muscle cells

- using recombinant adeno-associated virus vectors; Gregory M. Podsakoff, et al., 424/93.2, 93.21; 435/320.1; 514/44 [IMAGE AVAILABLE]
18. 5,856,152, Jan. 5, 1999, Hybrid adenovirus-AAV vector and methods of use therefor; James M. Wilson, et al., 435/320.1, 369 [IMAGE AVAILABLE]
19. 5,853,716, Dec. 29, 1998, Genetically engineered chimeric viruses for the treatment of diseases associated with viral transactivators; Peter J. Tattersall, et al., 424/93.2, 93.6; 435/357, 372.3; 536/24.1 [IMAGE AVAILABLE]
20. 5,851,826, Dec. 22, 1998, Helper virus-free herpesvirus vector packaging system; Cornel Fraefel, et al., 435/325, 69.1, 320.1 [IMAGE AVAILABLE]
21. 5,849,995, Dec. 15, 1998, Mouse model for Huntington's Disease and related DNA sequences; Michael Hayden, et al., 424/9.2; 435/320.1; 536/23.5, 24.31, 24.33 [IMAGE AVAILABLE]
22. 5,849,877, Dec. 15, 1998, Antigen-binding sites of antibody molecules specific for cancer antigens; David B. Ring, 530/387.1; 435/69.7, 70.21, 326; 530/387.3, 387.7, 388.1, 388.2, 388.8 [IMAGE AVAILABLE]
23. 5,846,528, Dec. 8, 1998, Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence; Gregory M. Podsakoff, et al., 424/93.2, 93.21; 435/320.1; 514/44, 814, 815 [IMAGE AVAILABLE]
24. 5,843,742, Dec. 1, 1998, Adeno-associated derived vector systems for gene delivery and integration into target cells; Georges Natsoulis, et al., 435/465, 366, 367, 369, 455 [IMAGE AVAILABLE]
25. 5,842,477, Dec. 1, 1998, Method for repairing cartilage; Gail K. Naughton, et al., 128/898; 623/11, 13 [IMAGE AVAILABLE]
26. 5,837,855, Nov. 17, 1998, Hairpin ribozymes; Bharat Chowrira, et al., 536/24.5; 435/320.1, 325, 354 [IMAGE AVAILABLE]
27. 5,837,838, Nov. 17, 1998, Bax inhibitor proteins; John C. Reed, et al., 536/23.1; 530/350 [IMAGE AVAILABLE]
28. 5,837,542, Nov. 17, 1998, Intercellular adhesion molecule-1 (ICAM-1) ribozymes; Susan Grimm, et al., 435/366, 6, 91.31, 320.1, 325; 536/23.1, 23.2, 24.5 [IMAGE AVAILABLE]
29. 5,837,484, Nov. 17, 1998, Stable cell lines capable of expressing the adeno-associated virus replication gene; James P. Trempe, et al., 435/69.1, 235.1, 320.1, 369 [IMAGE AVAILABLE]
30. 5,834,441, Nov. 10, 1998, Adeno-associated viral (AAV) liposomes and methods related thereto; Ramila Philip, et al., 514/44; 424/93.21, 450; 435/69.1, 320.1, 325, 458; 536/24.1 [IMAGE AVAILABLE]
31. 5,834,440, Nov. 10, 1998, Ribozyme therapy for the inhibition of restenosis; Tsvi Goldenberg, et al., 514/44; 435/6, 91.31, 320.1, 325, 366, 371, 375, 455; 536/23.1, 23.2, 24.5 [IMAGE AVAILABLE]
32. 5,834,182, Nov. 10, 1998, Method for increasing transduction of cells by adeno-associated virus vectors; Ian E. Alexander, et al., 435/5; 424/93.2; 435/6, 441, 442, 444, 446, 448, 456 [IMAGE AVAILABLE]
33. 5,831,062, Nov. 3, 1998, Use of the human interferon consensus gene for gene therapy; Milton W. Taylor, et al., 536/23.52, 24.1 [IMAGE AVAILABLE]
34. 5,831,008, Nov. 3, 1998, Retinoblastoma protein-interacting zinc finger proteins; Shi Huang, 530/350, 324, 327; 930/10 [IMAGE AVAILABLE]
35. 5,830,755, Nov. 3, 1998, T-cell receptors and their use in therapeutic and diagnostic methods; Michael Nishimura, et al., 435/325; 424/93.2; 435/6, 7.23, 69.1, 320.1; 530/387.7; 536/23.1 [IMAGE AVAILABLE]
36. 5,824,655, Oct. 20, 1998, Anti-transforming growth factor-beta gene therapy; Wayne A. Border, 514/44; 424/93.21, 93.7; 435/320.1, 352, 353, 354, 366; 514/2 [IMAGE AVAILABLE]
37. 5,821,235, Oct. 13, 1998, Gene therapy using the intestine; Susan June Henning, et al., 514/44; 424/93.21; 435/69.1, 70.3, 320.1; 604/264, 265, 266 [IMAGE AVAILABLE]
38. 5,817,796, Oct. 6, 1998, C-myc ribozymes having 2'-5'-linked adenylate residues; Dan T. Stinchcomb, et al., 536/24.5; 435/6, 91.31; 536/23.1, 23.2 [IMAGE AVAILABLE]
39. 5,817,784, Oct. 6, 1998, Neurogene; Lars Eyde Theill, et al., 536/23.1; 435/69.1, 252.3, 320.1; 530/350; 536/23.5, 24.31 [IMAGE AVAILABLE]
40. 5,811,304, Sep. 22, 1998, Nucleic acid molecules encoding retinoblastoma protein-interacting zinc finger proteins; Shi Huang, 435/325, 69.1, 243, 320.1, 375, 377, 410, 455; 536/23.1, 23.5 [IMAGE AVAILABLE]

41. 5,811,300, Sep. 22, 1998, TNF- $\alpha$  ribozymes; Sean Sullivan, et al., 435/366, 6, 91.31, 320.1, 325; 514/44; 536/23.1, 23.2, 24.5 [IMAGE AVAILABLE]
42. 5,811,275, Sep. 22, 1998, HIV-specific ribozymes; Flossie Wong-Staal, et al., 435/455; 424/93.2, 93.21; 435/320.1, 456; 536/23.1, 24.5 [IMAGE AVAILABLE]
43. 5,811,267, Sep. 22, 1998, Isolated nucleic acid molecules encoding antigen binding sites of antibody molecules specific for cancer antigens; David B. Ring, 435/69.7, 70.21; 530/387.1, 387.3, 387.7, 388.8, 388.85; 536/23.1, 23.4 [IMAGE AVAILABLE]
44. 5,807,743, Sep. 15, 1998, Interleukin-2 receptor gamma-chain ribozymes; Dan T. Stinchcomb, et al., 435/366, 6, 91.31, 320.1, 325; 536/23.1, 23.2, 24.5 [IMAGE AVAILABLE]
45. 5,807,685, Sep. 15, 1998, OspF, and S1 polypeptides in *Borrelia burgdorferi*; Richard A. Flavell, et al., 435/7.1; 514/2; 530/350 [IMAGE AVAILABLE]
46. 5,804,412, Sep. 8, 1998, Nucleic acids encoding sorting nexins and methods of using same; Gordon N. Gill, et al., 435/69.1, 320.1, 325; 530/300, 350; 536/23.1 [IMAGE AVAILABLE]
47. 5,801,030, Sep. 1, 1998, Methods and vectors for site-specific recombination; Duncan L. McVey, et al., 435/456, 320.1, 462; 536/23.1, 23.2 [IMAGE AVAILABLE]
48. 5,786,340, Jul. 28, 1998, Gene transfer to the intestine; Susan June Henning, et al., 514/44; 424/93.1 [IMAGE AVAILABLE]
49. 5,786,211, Jul. 28, 1998, Adeno-associated virus materials and methods; Philip R. Johnson, 435/320.1 [IMAGE AVAILABLE]
50. 5,780,447, Jul. 14, 1998, Recombinant adeno-associated viral vectors; Arthur W. Nienhuis, 514/44; 424/93.2, 93.21; 435/320.1, 325, 375, 456, 457 [IMAGE AVAILABLE]
51. 5,780,280, Jul. 14, 1998, Recombinant adeno-associated virus vectors; Jane S. Lebkowski, et al., 435/457, 235.1, 320.1, 465 [IMAGE AVAILABLE]
52. 5,780,244, Jul. 14, 1998, Changes in laminin subunit composition are diagnostic of Fukuyama congenital muscular dystrophy; Eva Engvall, et al., 435/7.21, 7.1, 7.94, 7.95, 960; 436/811 [IMAGE AVAILABLE]
53. 5,776,687, Jul. 7, 1998, Retinoid induced gene; Sunil Nagpal, et al., 435/6; 424/9.1, 9.2; 435/91.2; 536/23.1, 24.3, 24.33 [IMAGE AVAILABLE]
54. 5,773,289, Jun. 30, 1998, AAV directed targeted integration; Richard Jude Samulski, et al., 435/320.1, 69.1, 235.1, 325; 514/44 [IMAGE AVAILABLE]
55. 5,770,430, Jun. 23, 1998, Cellular injury response element and uses thereof; Stephen B. Howell, et al., 435/325, 320.1, 348, 366; 536/23.1, 24.1 [IMAGE AVAILABLE]
56. 5,766,877, Jun. 16, 1998, Genes encoding art, an agouti-related transcript; Kevin Lee Stark, et al., 435/69.1, 252.3, 254.11, 320.1, 325; 536/23.5 [IMAGE AVAILABLE]
57. 5,756,283, May 26, 1998, Method for improved production of recombinant adeno-associated viruses for gene therapy; James M. Wilson, et al., 435/5, 173.3, 236, 320.1, 366; 536/23.1, 24.1 [IMAGE AVAILABLE]
58. 5,753,500, May 19, 1998, Helper-free stocks of recombinant adeno-associated virus vectors; Thomas E. Shenk, et al., 435/320.1, 235.1 [IMAGE AVAILABLE]
59. 5,753,499, May 19, 1998, Viral vector complexes having adapters of predefined valence; Daniel Muelo, et al., 435/320.1, 235.1, 456; 514/44 [IMAGE AVAILABLE]
60. 5,747,245, May 5, 1998, Nucleic acids encoding Fas associated proteins and screening assays using same; John C. Reed, et al., 435/6, 91.2; 536/23.1, 24.3, 24.33 [IMAGE AVAILABLE]
61. 5,741,772, Apr. 21, 1998, Neurotrophic factor NNT-1; Ming-shi Chang, 514/2; 530/300, 350 [IMAGE AVAILABLE]
62. 5,741,706, Apr. 21, 1998, Anti-HIV ribozymes; Markley C. Leavitt, et al., 435/372, 6, 91.31, 320.1, 325, 366; 536/23.1, 23.2, 24.5 [IMAGE AVAILABLE]
63. 5,741,683, Apr. 21, 1998, In vitro packaging of adeno-associated virus DNA; Xiaohuai Zhou, et al., 435/457, 5, 235.1, 325, 366 [IMAGE AVAILABLE]
64. 5,731,295, Mar. 24, 1998, Method of reducing stromelysin RNA via ribozymes; Kenneth G. Draper, et al., 514/44; 435/6, 91.31, 325; 536/23.1, 23.2 [IMAGE AVAILABLE]

65. 5,714,383, Feb. 3, 1998, Method and reagent for treating chronic myelogenous leukemia; James D. Thompson, 435/366, 320.1; 514/44; 536/23.1 [IMAGE AVAILABLE]
66. 5,705,388, Jan. 6, 1998, CETP Ribozymes; Larry Couture, et al., 435/366, 6, 91.31, 320.1, 325; 514/44; 536/23.1, 23.2, 24.5 [IMAGE AVAILABLE]
67. 5,705,379, Jan. 6, 1998, Nucleotide sequences encoding a thermostable alkaline protease; David B. Wilson, et al., 435/220, 252.3, 253.5, 320.1; 536/23.2 [IMAGE AVAILABLE]
68. 5,700,927, Dec. 23, 1997, Tbc1 gene and uses thereof; Leonard Zon, et al., 536/23.5; 530/350 [IMAGE AVAILABLE]
69. 5,700,657, Dec. 23, 1997, Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby; Gary A. Beaudry, et al., 435/69.1, 91.33, 235.1, 325 [IMAGE AVAILABLE]
70. 5,693,532, Dec. 2, 1997, Respiratory syncytial virus ribozymes; James McSwiggen, et al., 435/366, 6, 91.31, 320.1, 325; 514/44; 536/23.1, 23.2, 24.5 [IMAGE AVAILABLE]
71. 5,693,531, Dec. 2, 1997, Vector systems for the generation of adeno-associated virus particles; John A. Chiorini, et al., 435/325; 424/93.1; 435/320.1 [IMAGE AVAILABLE]
72. 5,691,176, Nov. 25, 1997, Recombinant adeno-associated virus vector packaging cells and methods for use; Jane S. Lebkowski, et al., 435/457, 235.1, 320.1, 325, 465; 536/23.1 [IMAGE AVAILABLE]
73. 5,688,676, Nov. 18, 1997, In vitro packaging of adeno-associated virus DNA; Xiaohuai Zhou, et al., 435/457, 320.1, 456 [IMAGE AVAILABLE]
74. 5,688,675, Nov. 18, 1997, In vitro packaging of adeno-associated virus DNA; Xiaohuai Zhou, et al., 435/457, 320.1, 456 [IMAGE AVAILABLE]
75. 5,686,595, Nov. 11, 1997, Bel-2-associated proteins; John C. Reed, et al., 536/23.5, 23.1, 24.5 [IMAGE AVAILABLE]
76. 5,681,942, Oct. 28, 1997, Fanconi Anemia Type C gene; Manuel Buchwald, et al., 536/23.5, 24.2, 24.31, 24.33 [IMAGE AVAILABLE]
77. 5,681,745, Oct. 28, 1997, Biotin-binding containment systems; Przemyslaw Szafranski, et al., 435/325, 252.31, 252.33, 257.2, 320.1, 410; 536/23.7, 24.1 [IMAGE AVAILABLE]
78. 5,681,731, Oct. 28, 1997, Method for producing recombinant adeno-associated virus vectors; Jane S. Lebkowski, et al., 435/457, 320.1, 354, 366; 536/23.1 [IMAGE AVAILABLE]
79. 5,681,706, Oct. 28, 1997, Mammalian anoxia-responsive regulatory element; Garth R. Anderson, et al., 435/6, 69.1, 91.1, 320.1, 353, 375; 536/24.1 [IMAGE AVAILABLE]
80. 5,679,533, Oct. 21, 1997, Biotin-binding containment systems; Przemyslaw Szafranski, et al., 435/7.2, 7.32, 7.37, 262, 262.5, 320.1 [IMAGE AVAILABLE]
81. 5,677,158, Oct. 14, 1997, In vitro packaging of adeno-associated virus DNA; Xiaohuai Zhou, et al., 435/457, 235.1, 320.1 [IMAGE AVAILABLE]
82. 5,677,151, Oct. 14, 1997, Thermostable cellulase from a thermomonospora gene; David B. Wilson, et al., 435/72; 424/94.61; 435/96, 201, 252.3, 320.1; 536/23.7 [IMAGE AVAILABLE]
83. 5,670,361, Sep. 23, 1997, HIV-specific ribozymes; Flossie Wong-Staal, et al., 435/354, 320.1, 357, 363, 366, 372, 372.3; 536/23.1 [IMAGE AVAILABLE]
84. 5,663,064, Sep. 2, 1997, Ribozymes with RNA protein binding site; John M. Burke, et al., 514/44; 435/6, 91.31, 320.1, 325, 410; 536/23.1, 23.2, 24.5 [IMAGE AVAILABLE]
85. 5,658,785, Aug. 19, 1997, Adeno-associated virus materials and methods; Philip R. Johnson, 435/367, 320.1, 325, 369 [IMAGE AVAILABLE]
86. 5,658,780, Aug. 19, 1997, Rel a targeted ribozymes; Dan T. Stinchcomb, et al., 435/366, 6, 91.31, 320.1, 325; 514/44; 536/23.1, 23.2, 24.5 [IMAGE AVAILABLE]
87. 5,658,776, Aug. 19, 1997, Generation of high titers of recombinant AAV vectors; Terence R. Flotte, et al., 435/457, 91.4, 320.1, 352, 363, 366, 367, 369, 371 [IMAGE AVAILABLE]
88. 5,658,565, Aug. 19, 1997, Inducible nitric oxide synthase gene for treatment of disease; Timothy R. Billiar, et al., 424/93.21, 93.1, 93.2; 435/189, 191, 235.1, 320.1; 514/44; 536/23.1, 23.2, 23.5 [IMAGE AVAILABLE]
89. 5,656,451, Aug. 12, 1997, OspE, OspF, and S1 polypeptides in borrelia burgdorferi; Richard A. Flavell, et al., 435/69.1, 320.1, 325, 348, 366, 419; 530/350; 536/23.1 [IMAGE AVAILABLE]

90. 5,652,224, Jul. 29, 1997, Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism; James M. Wilson, et al., 514/44; 424/93.21; 435/320.1, 325, 354, 366, 369, 370, 456 [IMAGE AVAILABLE]
91. 5,650,491, Jul. 22, 1997, BCL-2-associated proteins; John C. Reed, et al., 530/350, 300 [IMAGE AVAILABLE]
92. 5,650,309, Jul. 22, 1997, Viral vectors; Flossie Wong-Staal, et al., 435/456, 320.1, 325, 366, 372, 372.3; 536/23.1, 24.1, 24.5 [IMAGE AVAILABLE]
93. 5,646,042, Jul. 8, 1997, C-myc targeted ribozymes; Dan T. Stinchcomb, et al., 435/366, 6, 91.31, 320.1, 325, 353; 514/44; 536/23.1, 23.2, 24.5 [IMAGE AVAILABLE]
94. 5,646,034, Jul. 8, 1997, Increasing rAAV titer; Michael Mamounas, et al., 435/325, 91.4, 320.1, 457 [IMAGE AVAILABLE]
95. 5,641,866, Jun. 24, 1997, Bcl-2-associated proteins; John C. Reed, et al., 530/387.7; 435/7.23; 530/388.1, 388.8, 389.7 [IMAGE AVAILABLE]
96. 5,637,456, Jun. 10, 1997, Rapid test for determining the amount of functionally inactive gene in a gene therapy vector preparation; Jack A. Roth, et al., 435/5, 6, 320.1 [IMAGE AVAILABLE]
97. 5,632,994, May 27, 1997, Fas associated proteins; John C. Reed, et al., 424/198.1, 185.1, 192.1; 435/7.1, 7.2, 7.9; 530/387.3, 387.9 [IMAGE AVAILABLE]
98. 5,631,359, May 20, 1997, Hairpin ribozymes; Bharat Chowrira, et al., 536/24.5; 435/320.1, 325, 354 [IMAGE AVAILABLE]
99. 5,622,856, Apr. 22, 1997, High efficiency helper system for AAV vector production; Georges Natsoulis, 435/325, 69.1, 320.1, 348, 366, 367, 369; 536/23.72 [IMAGE AVAILABLE]
100. 5,616,488, Apr. 1, 1997, IL-5 targeted ribozymes; Sean Sullivan, et al., 435/366, 6, 91.31, 320.1, 325; 514/44; 536/23.1, 23.2, 24.5 [IMAGE AVAILABLE]
101. 5,612,215, Mar. 18, 1997, Stromelysin targeted ribozymes; Kenneth G. Draper, et al., 435/366, 6, 91.31, 320.1, 325; 514/44; 536/23.1, 23.2, 24.5 [IMAGE AVAILABLE]
102. 5,604,090, Feb. 18, 1997, Method for increasing transduction of

- cells by adeno-associated virus vectors; Ian E. Alexander, et al., 435/5; 424/93.2; 435/456 [IMAGE AVAILABLE]
103. 5,599,706, Feb. 4, 1997, Ribozymes targeted to apo(a) mRNA; Dan T. Stinchcomb, et al., 435/366, 6, 91.31, 320.1, 325; 514/44; 536/23.1, 23.2, 24.5 [IMAGE AVAILABLE]
104. 5,589,377, Dec. 31, 1996, Recombinant adeno-associated virus vectors; Jane S. Lebkowski, et al., 435/369, 235.1, 320.1, 366, 367 [IMAGE AVAILABLE]
105. 5,587,308, Dec. 24, 1996, Modified \*\*adeno\*\*\*associated\*\* virus \*\*vector\*\* capable of expression from a novel \*\*promoter\*\*, Barrie J. Carter, et al., 435/371, 69.1, 320.1, 366; 536/23.1, 23.5, 24.1 [IMAGE AVAILABLE]
106. 5,580,761, Dec. 3, 1996, Method of conferring resistance to immunodeficiency viral infection; Wilson Greatbatch, et al., 435/91.32, 91.1, 91.3, 320.1, 351, 372, 372.3, 455; 536/23.1 [IMAGE AVAILABLE]
107. 5,539,094, Jul. 23, 1996, DNA encoding Bcl-2-associated proteins; John C. Reed, et al., 536/23.5; 435/69.1, 91.1, 320.1; 530/350 [IMAGE AVAILABLE]
108. 5,518,880, May 21, 1996, Methods for diagnosis of XSCID and kits thereof; Warren J. Leonard, et al., 435/6, 320.1, 810; 436/501; 536/22.1, 23.1, 24.1, 24.3, 24.31, 24.32, 24.33 [IMAGE AVAILABLE]
109. 5,474,935, Dec. 12, 1995, Adeno-associated virus (AAV)-based eucaryotic vectors; Saswati Chatterjee, et al., 435/320.1; 424/93.1, 93.2 [IMAGE AVAILABLE]
110. 5,436,146, Jul. 25, 1995, Helper-free stocks of recombinant adeno-associated virus vectors; Thomas E. Shenk, et al., 435/457, 91.4, 235.1, 320.1, 367, 465; 536/23.72 [IMAGE AVAILABLE]
111. 5,354,678, Oct. 11, 1994, Production of recombinant adeno-associated virus vectors; Jane S. Lebkowski, et al., 435/463, 235.1, 320.1, 366, 367, 369, 372 [IMAGE AVAILABLE]
112. 5,252,479, Oct. 12, 1993, Safe vector for gene therapy; Arun Srivastava, 435/235.1, 320.1, 372 [IMAGE AVAILABLE]
113. 5,173,414, Dec. 22, 1992, Production of recombinant adeno-associated virus vectors; Jane S. Lebkowski, et al., 435/91.4, 91.41, 320.1 [IMAGE AVAILABLE]

114. 5,139,941, Aug. 18, 1992, AAV transduction vectors; Nicholas Muzyczka, et al., 435/456, 320.1 [IMAGE AVAILABLE]
115. 4,797,368, Jan. 10, 1989, Adeno-associated virus as eukaryotic expression vector; Barrie J. Carter, et al., 435/320.1, 91.41, 91.42, 317.1 [IMAGE AVAILABLE]
- => d his
- (FILE 'USPAT' ENTERED AT 08:07:28 ON 24 FEB 1999)
- L1 553 S AAV OR ADENO ASSOCIATED OR ADENOASSOCIATED
- L2 163262 S TRANSDUC? OR VECTOR?
- L3 405 S L1(P)L2
- L4 115 S (PROMOTER# OR EXPRESSION CONTROL?)(P)L3
- => s specific?
- L5 1416093 SPECIFIC?
- 75% OF LIMIT FOR TOTAL ANSWERS REACHED
- => s l3(p)l5
- L6 116 L3(P)L5
- => s l6 not l4
- L7 49 L6 NOT L4
- => d l-49
1. 5,874,556, Feb. 23, 1999, Hybrid genes for use in the production of T.sub.H -independent cytotoxic T cells; Stephen D. Lupton, et al., 536/23.1; 435/69.1, 69.5, 69.52, 69.7, 252.3, 320.1, 363, 366, 372, 372.3; 536/23.4, 23.52 [IMAGE AVAILABLE]
2. 5,874,273, Feb. 23, 1999, G-beta-gamma regulated phosphatidylinositol-3' kinase; Len Stephens, et al., 435/194, 252.3, 320.1, 325, 358, 365, 366; 530/350, 829; 536/23.2, 23.4, 23.5 [IMAGE AVAILABLE]
3. 5,871,986, Feb. 16, 1999, Use of a baculovirus to express and exogenous gene in a mammalian cell; Frederick M. Boyce, 435/183, 320.1, 325; 536/23.2 [IMAGE AVAILABLE]
4. 5,871,931, Feb. 16, 1999, Methods for detecting mammalian tub protein and RNA; Patrick W. Kleyn, et al., 435/6, 4, 7.1, 7.92, 7.95 [IMAGE AVAILABLE]
5. 5,871,464, Feb. 16, 1999, Perfusion apparatus and methods for pharmaceutical delivery; Karl Tryggvason, et al., 604/132 [IMAGE AVAILABLE]
6. 5,869,271, Feb. 9, 1999, G-beta-gamma regulated phosphatidylinositol-3' kinase; Len Stephens, et al., 435/15, 193, 194; 530/350, 829; 536/23.2, 23.5 [IMAGE AVAILABLE]
7. 5,869,265, Feb. 9, 1999, Ileal bile acid transporter compositions and methods; Paul A. Dawson, 435/7.2, 69.1, 252.3, 254.11, 320.1, 325; 530/350; 536/23.5 [IMAGE AVAILABLE]
8. 5,869,040, Feb. 9, 1999, Gene therapy methods and compositions; Xiao-Oiang Qin, 424/93.21; 435/69.1, 320.1, 366; 536/23.5 [IMAGE AVAILABLE]
9. 5,866,412, Feb. 2, 1999, Chromosome 18 marker; Hong Chen, et al., 435/320.1, 243, 325; 536/23.1, 23.5 [IMAGE AVAILABLE]
10. 5,861,310, Jan. 19, 1999, Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor; Gordon J. Freeman, et al., 435/325; 424/93.2, 277.1; 435/375 [IMAGE AVAILABLE]
11. 5,861,239, Jan. 19, 1999, Methods for identifying compounds that modulate mammalian tub protein activity; Patrick W. Kleyn, et al., 435/4 [IMAGE AVAILABLE]
12. 5,859,201, Jan. 12, 1999, G-beta-gamma regulated phosphatidylinositol-3' kinase; Len Stephens, et al., 530/350; 435/69.7; 530/829 [IMAGE AVAILABLE]
13. 5,859,183, Jan. 12, 1999, Altered telomere repeat binding factor; Titia de Lange, et al., 530/300, 350 [IMAGE AVAILABLE]
14. 5,858,776, Jan. 12, 1999, Tumor cells with increased immunogenicity and uses therefor; Suzanne Ostrand-Rosenberg, et al., 435/325, 69.1, 320.1, 354, 366, 375 [IMAGE AVAILABLE]
15. 5,858,711, Jan. 12, 1999, NF-AT-interacting protein NIP45 and methods of use therefor; Laurie H. Glimcher, et al., 435/69.1, 29, 320.1, 325; 536/23.5, 24.5 [IMAGE AVAILABLE]
16. 5,858,355, Jan. 12, 1999, IRAP gene as treatment for arthritis; Joseph C. Glorioso, et al., 424/93.21, 93.2; 514/44 [IMAGE AVAILABLE]
17. 5,856,153, Jan. 5, 1999, Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases; Gerard Tiraby, et al., 424/93.2; 435/69.7, 194, 227, 320.1, 325, 353, 354, 363, 366; 514/44 [IMAGE AVAILABLE]
18. 5,856,133, Jan. 5, 1999, G-beta-gamma regulated phosphatidylinositol-3' kinase; Len Stephens, et al., 435/69.2, 69.1, 194, 252.3; 530/350, 829; 536/23.5 [IMAGE AVAILABLE]

19. 5,856,132, Jan. 5, 1999, G-beta-gamma regulated phosphatidylinositol-3' kinase; Len Stephens, et al., 435/69.2, 69.1, 69.7, 194, 252.3, 320.1, 325, 358, 365, 366; 530/350, 829; 536/23.2, 23.4, 23.5 [IMAGE AVAILABLE]
20. 5,846,821, Dec. 8, 1998, Metal-regulated transporters and uses therefor; Mary Lou Guerinot, et al., 435/320.1, 6, 69.1, 325; 436/501; 536/23.1, 24.1, 24.3, 24.31, 24.32, 24.33 [IMAGE AVAILABLE]
21. 5,846,780, Dec. 8, 1998, Murine RATH gene; Douglas Adam Levinson, et al., 435/69.2, 320.1, 325; 536/23.1, 23.5 [IMAGE AVAILABLE]
22. 5,843,697, Dec. 1, 1998, Cells expressing IL-10 receptor and the CRFB4 gene product, an IL-10 receptor accessory protein; Sidney Pestka, et al., 435/29, 7.21, 320.1, 325; 536/23.5 [IMAGE AVAILABLE]
23. 5,837,693, Nov. 17, 1998, Intravenous hormone polypeptide delivery by salivary gland expression; Michael German, et al., 514/44; 424/93.21; 435/320.1, 325; 536/23.1 [IMAGE AVAILABLE]
24. 5,834,306, Nov. 10, 1998, Tissue specific hypoxia regulated therapeutic constructs; Keith A. Webster, et al., 435/320.1; 536/24.1 [IMAGE AVAILABLE]
25. 5,834,293, Nov. 10, 1998, Cytochrome P450 arachidonic acid epoxigenase genetic mutation associated with hypertension; Jorge H. Capdevila, et al., 435/325, 6, 348, 358, 365, 367; 536/23.1 [IMAGE AVAILABLE]
26. 5,830,850, Nov. 3, 1998, Methods for the treatment of bone resorption disorders, including osteoporosis; Bruce D. Gelb, et al., 514/2; 436/501; 514/44 [IMAGE AVAILABLE]
27. 5,827,702, Oct. 27, 1998, Ocular gene therapy; R. Andrew Cuthbertson, 514/44; 435/320.1, 455, 486 [IMAGE AVAILABLE]
28. 5,824,794, Oct. 20, 1998, Human stromelysin-1 promoter; Paula Ann Borden, et al., 536/24.1; 435/252.3, 320.1, 325, 366; 536/23.5 [IMAGE AVAILABLE]
29. 5,817,762, Oct. 6, 1998, Mammalian tub protein; Patrick W. Kleyn, et al., 530/350; 536/23.5 [IMAGE AVAILABLE]
30. 5,817,628, Oct. 6, 1998, Dymorphin a suppression of natural killer cell activity; Mary Jeanne Kreek, 514/13, 15; 530/327, 328 [IMAGE AVAILABLE]
31. 5,814,500, Sep. 29, 1998, Delivery construct for antisense nucleic acids and methods of use; Harry C. Dietz, 435/455, 6, 320.1, 375; 536/24.1, 24.5 [IMAGE AVAILABLE]
32. 5,789,390, Aug. 4, 1998, Method for preparing recombinant adeno-associated viruses (AAV), and uses thereof; Vincent Descamps, et al., 514/44; 424/199.1, 233.1; 435/69.1, 235.1; 536/23.5 [IMAGE AVAILABLE]
33. 5,770,690, Jun. 23, 1998, Bax omega protein and methods; Catherine Mastroni Bitler, et al., 530/324, 329, 350 [IMAGE AVAILABLE]
34. 5,750,396, May 12, 1998, Stable virus packaging cell lines; Yanping Yang, et al., 435/357, 320.1, 366; 536/23.72, 24.1 [IMAGE AVAILABLE]
35. 5,747,292, May 5, 1998, Chimeric cytokine receptors in lymphocytes; Philip D. Greenberg, et al., 435/69.7, 252.3, 320.1; 530/350; 536/23.4 [IMAGE AVAILABLE]
36. 5,744,368, Apr. 28, 1998, Methods for the detection of soluble amyloid beta-protein (beta.AP) or soluble transthyretin (TTR); Dmitry Y. Goldgaber, et al., 436/501; 435/7.8; 436/503, 504, 518, 804 [IMAGE AVAILABLE]
37. 5,731,182, Mar. 24, 1998, Non-mammalian DNA virus to express an exogenous gene in a mammalian cell; Frederick M. Boyce, 435/183, 69.1, 70.1, 320.1 [IMAGE AVAILABLE]
38. 5,716,622, Feb. 10, 1998, Functionally active regions of signal transducer and activators of transcription; James E. Darnell, Jr., et al., 424/185.1, 193.1; 530/350, 403 [IMAGE AVAILABLE]
39. 5,712,114, Jan. 27, 1998, Compositions for expression of proteins in host cells using a procollagen signal sequence; John A. Mankovich, et al., 435/69.1, 254.2, 255.7, 320.1, 325; 536/23.1, 24.1 [IMAGE AVAILABLE]
40. 5,693,508, Dec. 2, 1997, Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats; Lung-Ji Chang, 435/6, 69.1, 320.1, 456, 465; 536/24.1 [IMAGE AVAILABLE]
41. 5,677,139, Oct. 14, 1997, In vitro differentiation of CD34.sup.+ progenitor cells into T lymphocytes; R. Paul Johnson, et al., 435/29, 363, 372.3, 373 [IMAGE AVAILABLE]
42. 5,672,508, Sep. 30, 1997, Inhibitors of cell-cycle progression, and uses related thereto; Jeno Gyuris, et al., 435/320.1; 536/23.4, 23.5 [IMAGE AVAILABLE]

43. 5,656,465, Aug. 12, 1997, Methods of in vivo gene delivery; Dennis L. Panicali, et al., 435/456, 320.1 [IMAGE AVAILABLE]
44. 5,648,259, Jul. 15, 1997, Polypeptides having NMDA receptor activity, nucleic acids encoding those polypeptides and applications; Jacques Mallet, et al., 435/252.3, 69.1; 530/350; 536/23.5 [IMAGE AVAILABLE]
45. 5,646,040, Jul. 8, 1997, Mammalian tub gene; Patrick W. Kley, et al., 435/325, 320.1, 348, 357, 358, 364, 365, 369, 419; 536/23.5, 24.3, 24.31 [IMAGE AVAILABLE]
46. 5,580,703, Dec. 3, 1996, Human adeno-associated virus integration site DNA and uses thereof; Robert M. Kotin, et al., 435/320.1; 536/23.5, 23.72 [IMAGE AVAILABLE]
47. 5,556,837, Sep. 17, 1996, Methods for treating addictive disorders; Eric J. Nestler, et al., 514/21; 424/570; 514/811, 812, 813 [IMAGE AVAILABLE]
48. 5,478,745, Dec. 26, 1995, Recombinant viral vector system; Richard J. Samulski, et al., 435/320.1, 69.1; 536/23.1, 24.1 [IMAGE AVAILABLE]
49. 4,159,776, Jul. 3, 1979, Tower crane; Carl F. Holter, 212/239 [IMAGE AVAILABLE]  
=> save all 1475470/L  
L# LIST 'L1-L7' HAS BEEN SAVED AS 'L475470/L'  
75% OF LIMIT FOR SAVED L# LISTS REACHED  
=> log hold  
SESSION WILL BE HELD FOR 30 MINUTES  
U.S. Patent & Trademark Office SESSION SUSPENDED AT 09:20:13 ON 24 FEB 1999